{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:16:44Z","timestamp":1794392204826,"version":"4.9.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mutational profile of cancer reflects the activity of the mutagenic processes which have been operative throughout the lineage of the cancer cell. These processes leave characteristic profiles of somatic mutations called mutational signatures. Mutational signatures, including single-base substitution (SBS) signatures, may reflect the effects of exogenous or endogenous exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used polygenic risk scores (PRS) to summarize common germline variation associated with cancer risk and other cancer-related traits and examined the association between somatic mutational profiles and germline PRS in 12 cancer types from The Cancer Genome Atlas. Somatic mutational profiles were constructed from whole-exome sequencing data of primary tumors. PRS were calculated for the 12 selected cancer types and 9 non-cancer traits, including cancer risk determinants, hormonal factors, and immune-mediated inflammatory diseases, using germline genetic data and published summary statistics from genome-wide association studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found 17 statistically significant associations between somatic mutational profiles and germline PRS after Bonferroni correction (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 3.15 \u00d7 10\n                      <jats:sup>\u22125<\/jats:sup>\n                      ), including positive associations between germline inflammatory bowel disease PRS and number of somatic mutations attributed to signature SBS1 in prostate cancer and APOBEC-related signatures in breast cancer. Positive associations were also found between age at menarche PRS and mutation counts of SBS1 in overall and estrogen receptor-positive breast cancer. Consistent with prior studies that found an inverse association between the pubertal development PRS and risk of prostate cancer, likely reflecting hormone-related mechanisms, we found an inverse association between age at menarche PRS and mutation counts of SBS1 in prostate cancer. Inverse associations were also found between several cancer PRS and tumor mutation counts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis suggests that there are robust associations between tumor somatic mutational profiles and germline PRS. These may reflect the mechanisms through hormone regulation and immune responses that contribute to cancer etiology and drive cancer progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-022-01016-y","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T19:02:56Z","timestamp":1644519776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Somatic mutational profiles and germline polygenic risk scores in human cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Yuxi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing J.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmil B.","family":"Alexandrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-8103","authenticated-orcid":false,"given":"Peter","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"issue":"7793","key":"1016_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature."},{"issue":"9","key":"1016_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrg3729","volume":"15","author":"T Helleday","year":"2014","unstructured":"Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15(9):585\u201398.","journal-title":"Nat Rev Genet"},{"issue":"7239","key":"1016_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719\u201324.","journal-title":"Nature."},{"issue":"1","key":"1016_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","volume":"3","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3(1):246\u201359.","journal-title":"Cell Rep"},{"issue":"12","key":"1016_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/ng.3441","volume":"47","author":"LB Alexandrov","year":"2015","unstructured":"Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402\u20137.","journal-title":"Nat Genet"},{"issue":"7463","key":"1016_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature."},{"issue":"7793","key":"1016_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Consortium ITP-CAoWG","year":"2020","unstructured":"Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82\u201393.","journal-title":"Nature."},{"issue":"7605","key":"1016_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354.","journal-title":"Nature."},{"issue":"D1","key":"1016_CR9","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47(D1):D941\u2013D7.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1016_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"1","key":"1016_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1016_CR12","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1016_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1016_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/gm175","volume":"2","author":"GP Pfeifer","year":"2010","unstructured":"Pfeifer GP. Environmental exposures and mutational patterns of cancer genomes. Genome Med. 2010;2(8):54.","journal-title":"Genome Med"},{"key":"1016_CR15","first-page":"259","volume":"301","author":"GP Pfeifer","year":"2006","unstructured":"Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol. 2006;301:259\u201381.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"1016_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tig.2019.04.005","volume":"35","author":"JR Ramroop","year":"2019","unstructured":"Ramroop JR, Gerber MM, Toland AE. Germline variants impact somatic events during tumorigenesis. Trends Genet. 2019;35(7):515\u201326.","journal-title":"Trends Genet"},{"key":"1016_CR17","doi-asserted-by":"publisher","first-page":"12064","DOI":"10.1038\/ncomms12064","volume":"7","author":"CD Robles-Espinoza","year":"2016","unstructured":"Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP, Alexandrov LB, Pornputtapong N, et al. Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun. 2016;7:12064.","journal-title":"Nat Commun"},{"issue":"1","key":"1016_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12864-018-4906-4","volume":"19","author":"J Guo","year":"2018","unstructured":"Guo J, Huang J, Zhou Y, Zhou Y, Yu L, Li H, et al. Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population. BMC Genomics. 2018;19(1):538.","journal-title":"BMC Genomics"},{"issue":"6","key":"1016_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/bjc.2016.223","volume":"115","author":"B Zhu","year":"2016","unstructured":"Zhu B, Mukherjee A, Machiela MJ, Song L, Hua X, Shi J, et al. An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer. Br J Cancer. 2016;115(6):752\u201360.","journal-title":"Br J Cancer"},{"issue":"11","key":"1016_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/ng.3670","volume":"48","author":"CD Middlebrooks","year":"2016","unstructured":"Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48(11):1330\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"1016_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2159-8290.CD-16-1045","volume":"7","author":"H Carter","year":"2017","unstructured":"Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, et al. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 2017;7(4):410\u201323.","journal-title":"Cancer Discov"},{"key":"1016_CR22","doi-asserted-by":"crossref","unstructured":"Sun X, Xue A, Qi T, Chen D, Shi D, Wu Y, et al. Tumor Mutational Burden Is Polygenic and Genetically Associated with Complex Traits and Diseases. Cancer Res. 2021;81(5):1230-9.","DOI":"10.1158\/0008-5472.CAN-20-3459"},{"issue":"2","key":"1016_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","volume":"173","author":"C Hutter","year":"2018","unstructured":"Hutter C, Zenklusen JC. The Cancer Genome Atlas: creating lasting value beyond its data. Cell. 2018;173(2):283\u20135.","journal-title":"Cell."},{"issue":"1A","key":"1016_CR24","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68\u201377.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"12","key":"1016_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12):1109\u201312.","journal-title":"N Engl J Med"},{"issue":"2","key":"1016_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355\u201370 e14.","journal-title":"Cell."},{"issue":"11","key":"1016_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"5","key":"1016_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","volume":"42","author":"T Bosse","year":"2018","unstructured":"Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol. 2018;42(5):561\u20138.","journal-title":"Am J Surg Pathol"},{"key":"1016_CR29","first-page":"159","volume":"17","author":"JN Nojadeh","year":"2018","unstructured":"Nojadeh JN, Behrouz Sharif S, Sakhinia E. Microsatellite instability in colorectal cancer. EXCLI J. 2018;17:159\u201368.","journal-title":"EXCLI J"},{"issue":"5","key":"1016_CR30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171(5):1042\u201356 e10.","journal-title":"Cell."},{"issue":"10","key":"1016_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/ng.3643","volume":"48","author":"S McCarthy","year":"2016","unstructured":"McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48(10):1279\u201383.","journal-title":"Nat Genet"},{"issue":"D1","key":"1016_CR32","doi-asserted-by":"publisher","first-page":"D1005","DOI":"10.1093\/nar\/gky1120","volume":"47","author":"A Buniello","year":"2019","unstructured":"Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005\u2013D12.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1016_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ajhg.2020.08.025","volume":"107","author":"LG Fritsche","year":"2020","unstructured":"Fritsche LG, Patil S, Beesley LJ, VandeHaar P, Salvatore M, Ma Y, et al. Cancer PRSweb: an online repository with polygenic risk scores for major cancer traits and their evaluation in two independent biobanks. Am J Hum Genet. 2020;107(5):815\u201336.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1016_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","volume":"53","author":"SA Lambert","year":"2021","unstructured":"Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet. 2021;53(4):420\u20135.","journal-title":"Nat Genet"},{"key":"1016_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience."},{"issue":"1","key":"1016_CR36","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41467-020-16293-7","volume":"11","author":"T Qing","year":"2020","unstructured":"Qing T, Mohsen H, Marczyk M, Ye Y, O\u2019Meara T, Zhao H, et al. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. Nat Commun. 2020;11(1):2438.","journal-title":"Nat Commun"},{"key":"1016_CR37","first-page":"74","volume-title":"Causal inference: what if","author":"MA Hern\u00e1n","year":"2020","unstructured":"Hern\u00e1n MA, Robins JM. Causal inference: what if. Boca Raton: Chapman & Hall\/CRC; 2020. p. 74\u20135."},{"issue":"2","key":"1016_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ajhg.2014.12.021","volume":"96","author":"H Aschard","year":"2015","unstructured":"Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am J Hum Genet. 2015;96(2):329\u201339.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"1016_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/1055-9965.EPI-19-1087","volume":"29","author":"YJ Heng","year":"2020","unstructured":"Heng YJ, Hankinson SE, Wang J, Alexandrov LB, Ambrosone CB, de Andrade VP, et al. The association of modifiable breast cancer risk factors and somatic genomic alterations in breast tumors: The Cancer Genome Atlas Network. Cancer Epidemiol Biomarkers Prev. 2020;29(3):599\u2013605.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"1016_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2008.12.002","volume":"136","author":"T Kawase","year":"2009","unstructured":"Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell. 2009;136(3):535\u201350.","journal-title":"Cell."},{"issue":"12","key":"1016_CR41","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/ng.3785","volume":"49","author":"RL Milne","year":"2017","unstructured":"Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindstrom S, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12):1767\u201378.","journal-title":"Nat Genet"},{"issue":"7678","key":"1016_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature24284","volume":"551","author":"K Michailidou","year":"2017","unstructured":"Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92\u20134.","journal-title":"Nature."},{"issue":"4","key":"1016_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ng.3242","volume":"47","author":"K Michailidou","year":"2015","unstructured":"Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373\u201380.","journal-title":"Nat Genet"},{"issue":"4","key":"1016_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ng.2563","volume":"45","author":"K Michailidou","year":"2013","unstructured":"Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353\u201361 61e1-2.","journal-title":"Nat Genet"},{"issue":"2","key":"1016_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2020.03.053","volume":"181","author":"O Rozenblatt-Rosen","year":"2020","unstructured":"Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, et al. The Human Tumor Atlas Network: charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181(2):236\u201349.","journal-title":"Cell."},{"issue":"11","key":"1016_CR46","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","author":"Collaborative Group on Hormonal Factors in Breast C","year":"2012","unstructured":"Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141\u201351.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1016_CR47","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/ng.3841","volume":"49","author":"FR Day","year":"2017","unstructured":"Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet. 2017;49(6):834\u201341.","journal-title":"Nat Genet"},{"issue":"4","key":"1016_CR48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajhb.22222","volume":"24","author":"DJ Barker","year":"2012","unstructured":"Barker DJ, Osmond C, Thornburg KL, Kajantie E, Eriksson JG. A possible link between the pubertal growth of girls and prostate cancer in their sons. Am J Hum Biol. 2012;24(4):406\u201310.","journal-title":"Am J Hum Biol"},{"issue":"2","key":"1016_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.10810","volume":"103","author":"GG Giles","year":"2003","unstructured":"Giles GG, Severi G, English DR, McCredie MR, MacInnis R, Boyle P, et al. Early growth, adult body size and prostate cancer risk. Int J Cancer. 2003;103(2):241\u20135.","journal-title":"Int J Cancer"},{"issue":"16","key":"1016_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/jnci\/88.16.1118","volume":"88","author":"PH Gann","year":"1996","unstructured":"Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118\u201326.","journal-title":"J Natl Cancer Inst"},{"key":"1016_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12916-016-0602-x","volume":"14","author":"C Bonilla","year":"2016","unstructured":"Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, et al. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med. 2016;14:66.","journal-title":"BMC Med"},{"issue":"5350","key":"1016_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.279.5350.563","volume":"279","author":"JM Chan","year":"1998","unstructured":"Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563\u20136.","journal-title":"Science."},{"issue":"4","key":"1016_CR53","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.beem.2013.05.001","volume":"27","author":"M Grossmann","year":"2013","unstructured":"Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab. 2013;27(4):603\u201316.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"1016_CR54","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1002\/ijc.24202","volume":"124","author":"MA Rowlands","year":"2009","unstructured":"Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124(10):2416\u201329.","journal-title":"Int J Cancer"},{"issue":"2","key":"1016_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00345-012-1009-8","volume":"31","author":"A Salonia","year":"2013","unstructured":"Salonia A, Abdollah F, Capitanio U, Suardi N, Gallina A, Castagna G, et al. Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World J Urol. 2013;31(2):267\u201373.","journal-title":"World J Urol"},{"issue":"8","key":"1016_CR56","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1210\/jc.2005-2318","volume":"91","author":"J Sandhu","year":"2006","unstructured":"Sandhu J, Davey Smith G, Holly J, Cole TJ, Ben-Shlomo Y. Timing of puberty determines serum insulin-like growth factor-I in late adulthood. J Clin Endocrinol Metab. 2006;91(8):3150\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1016_CR57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrc3434","volume":"13","author":"S Sutcliffe","year":"2013","unstructured":"Sutcliffe S, Colditz GA. Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer. 2013;13(3):208\u2013518.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1016_CR58","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/0008-5472.CAN-15-1551","volume":"76","author":"RC Travis","year":"2016","unstructured":"Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016;76(8):2288\u2013300.","journal-title":"Cancer Res"},{"issue":"20","key":"1016_CR59","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","volume":"22","author":"JE Axelrad","year":"2016","unstructured":"Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794\u2013801.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1016_CR60","first-page":"450","volume":"26","author":"L Biancone","year":"2020","unstructured":"Biancone L, Armuzzi A, Scribano ML, Castiglione F, D\u2019Inca R, Orlando A, et al. Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD Study. Inflamm Bowel Dis. 2020;26(3):450\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1016_CR61","first-page":"571","volume":"11","author":"O Hovde","year":"2017","unstructured":"Hovde O, Hoivik ML, Henriksen M, Solberg IC, Smastuen MC, Moum BA. Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN Study. J Crohns Colitis. 2017;11(5):571\u20137.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"1016_CR62","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1016\/j.ijsu.2014.05.022","volume":"12","author":"G Pellino","year":"2014","unstructured":"Pellino G, Sciaudone G, Patturelli M, Candilio G, De Fatico GS, Landino I, et al. Relatives of Crohn\u2019s disease patients and breast cancer: an overlooked condition. Int J Surg. 2014;12(Suppl 1):S156\u20138.","journal-title":"Int J Surg"},{"issue":"Suppl 2","key":"1016_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2036.1996.22164020.x","volume":"10","author":"F Cominelli","year":"1996","unstructured":"Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther. 1996;10(Suppl 2):49\u201353 discussion 4.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1016_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/07357900009012171","volume":"18","author":"LJ Miller","year":"2000","unstructured":"Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000;18(4):293\u2013302.","journal-title":"Cancer Invest"},{"issue":"7","key":"1016_CR65","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/sj.gene.6363888","volume":"3","author":"L Vijgen","year":"2002","unstructured":"Vijgen L, Van Gysel M, Rector A, Thoelen I, Esters N, Ceelen T, et al. Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun. 2002;3(7):400\u20136.","journal-title":"Genes Immun"},{"issue":"8","key":"1016_CR66","volume":"7","author":"J Wang","year":"2019","unstructured":"Wang J, Shi Y, Wang G, Dong S, Yang D, Zuo X. The association between interleukin-1 polymorphisms and their protein expression in Chinese Han patients with breast cancer. Mol Genet Genomic Med. 2019;7(8):e804.","journal-title":"Mol Genet Genomic Med"},{"issue":"4","key":"1016_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ol.2020.11981","volume":"20","author":"J Zhou","year":"2020","unstructured":"Zhou J, Yang R. Identification of key pathways and genes shared between Crohn\u2019s disease and breast cancer using bioinformatics analysis. Oncol Lett. 2020;20(4):119.","journal-title":"Oncol Lett"},{"issue":"3","key":"1016_CR68","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clinre.2019.07.003","volume":"44","author":"M Chen","year":"2020","unstructured":"Chen M, Yuan C, Xu T. An increase in prostate cancer diagnosis during inflammatory bowel disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020;44(3):302\u20139.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"1016_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41391-019-0177-7","volume":"23","author":"Y Ge","year":"2020","unstructured":"Ge Y, Shi Q, Yao W, Cheng Y, Ma G. The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23(1):53\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"1016_CR70","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/ijc.33048","volume":"147","author":"TJ Meyers","year":"2020","unstructured":"Meyers TJ, Weiner AB, Graff RE, Desai AS, Cooley LF, Catalona WJ, et al. Association between inflammatory bowel disease and prostate cancer: a large-scale, prospective, population-based study. Int J Cancer. 2020;147(10):2735\u201342.","journal-title":"Int J Cancer"},{"issue":"5","key":"1016_CR71","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2018.11.039","volume":"75","author":"JA Burns","year":"2019","unstructured":"Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019;75(5):846\u201352.","journal-title":"Eur Urol"},{"key":"1016_CR72","doi-asserted-by":"crossref","unstructured":"Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, et al. FOLH1\/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. 2016;1(12):e88634.","DOI":"10.1172\/jci.insight.88634"},{"issue":"21","key":"1016_CR73","doi-asserted-by":"publisher","first-page":"9070","DOI":"10.1158\/0008-5472.CAN-08-2328","volume":"68","author":"V Yao","year":"2008","unstructured":"Yao V, Parwani A, Maier C, Heston WD, Bacich DJ. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008;68(21):9070\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"1016_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037139","volume":"7","author":"T Zhang","year":"2012","unstructured":"Zhang T, Song B, Zhu W, Xu X, Gong QQ, Morando C, et al. An ileal Crohn\u2019s disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS One. 2012;7(5):e37139.","journal-title":"PLoS One"},{"issue":"1","key":"1016_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215(1):159\u201375.","journal-title":"J Exp Med"},{"issue":"Suppl 2","key":"1016_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2036.18.s2.2.x","volume":"18","author":"P Munkholm","year":"2003","unstructured":"Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1\u20135.","journal-title":"Aliment Pharmacol Ther"},{"key":"1016_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcancer.2019.05.001","volume":"64","author":"MS Nadeem","year":"2020","unstructured":"Nadeem MS, Kumar V, Al-Abbasi FA, Kamal MA, Anwar F. Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol. 2020;64:51\u201360.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1016_CR78","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2019.09.007","volume":"31","author":"JM Genkinger","year":"2020","unstructured":"Genkinger JM, Wu K, Wang M, Albanes D, Black A, van den Brandt PA, et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in the Pooling Project of Prospective Studies of Diet and Cancer. Ann Oncol. 2020;31(1):103\u201314.","journal-title":"Ann Oncol"},{"issue":"7","key":"1016_CR79","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/annonc\/mdr603","volume":"23","author":"A Discacciati","year":"2012","unstructured":"Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665\u201371.","journal-title":"Ann Oncol"},{"issue":"4","key":"1016_CR80","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1158\/1940-6207.CAPR-10-0229","volume":"4","author":"Y Cao","year":"2011","unstructured":"Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486\u2013501.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"1016_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1055-9965.EPI-06-0754","volume":"16","author":"C Rodriguez","year":"2007","unstructured":"Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(1):63\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"1016_CR82","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1158\/1055-9965.EPI-06-0477","volume":"15","author":"Z Gong","year":"2006","unstructured":"Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1977\u201383.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"1016_CR83","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/cncr.20856","volume":"103","author":"J Baillargeon","year":"2005","unstructured":"Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103(5):1092\u20135.","journal-title":"Cancer."},{"issue":"2","key":"1016_CR84","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/cncr.21603","volume":"106","author":"AR Kristal","year":"2006","unstructured":"Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106(2):320\u20138.","journal-title":"Cancer."},{"issue":"19","key":"1016_CR85","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.298.19.2275","volume":"298","author":"LL Banez","year":"2007","unstructured":"Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275\u201380.","journal-title":"JAMA."},{"issue":"1","key":"1016_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12916-017-0876-7","volume":"15","author":"A Perez-Cornago","year":"2017","unstructured":"Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tjonneland A, Olsen A, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med. 2017;15(1):115.","journal-title":"BMC Med"},{"issue":"11","key":"1016_CR87","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10552-015-0654-9","volume":"26","author":"NM Davies","year":"2015","unstructured":"Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015;26(11):1603\u201316.","journal-title":"Cancer Causes Control"},{"key":"1016_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1203","volume":"369","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey SG. Use of genetic variation to separate the effects of early and later life adiposity on disease risk: Mendelian randomisation study. BMJ. 2020;369:m1203.","journal-title":"BMJ."},{"key":"1016_CR89","doi-asserted-by":"crossref","unstructured":"Busch AS, Hojgaard B, Hagen CP, Teilmann G. Obesity Is Associated with Earlier Pubertal Onset in Boys. J Clin Endocrinol Metab. 2020;105(4):e1667-e1672.","DOI":"10.1210\/clinem\/dgz222"},{"issue":"17","key":"1016_CR90","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.18.02462","volume":"37","author":"MK Downer","year":"2019","unstructured":"Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, Giovannucci EL, et al. Alcohol intake and risk of lethal prostate cancer in the health professionals follow-up study. J Clin Oncol. 2019;37(17):1499\u2013511.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1016_CR91","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/EDE.0000000000000081","volume":"25","author":"TJ VanderWeele","year":"2014","unstructured":"VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology. 2014;25(3):427\u201335.","journal-title":"Epidemiology."},{"issue":"7187","key":"1016_CR92","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/452537a","volume":"452","author":"SJ Chanock","year":"2008","unstructured":"Chanock SJ, Hunter DJ. Genomics: when the smoke clears. Nature. 2008;452(7187):537\u20138.","journal-title":"Nature."},{"issue":"10","key":"1016_CR93","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/aje\/kwr467","volume":"175","author":"TJ VanderWeele","year":"2012","unstructured":"VanderWeele TJ, Asomaning K, Tchetgen Tchetgen EJ, Han Y, Spitz MR, Shete S, et al. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol. 2012;175(10):1013\u201320.","journal-title":"Am J Epidemiol"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01016-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:28:50Z","timestamp":1650277730000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01016-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.28.428663","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for Institutional Review Board Approval at our institution (Harvard T.H. Chan School of Public Health) was waived for this study as all data used from this project had previously been generated as part of The Cancer Genome Atlas Project, and none of the results reported in this manuscript can be used to identify individual patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}